leisure time -WSS

leisure time

author：focus 2025-09-02 11:34:18 - browse：7

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare has a new plan to address drug shortages

WSS

Roche drug slashes death risk in early

STAT Summit: The economic case for universal basic health care

Sanofi seeks simpler, safer CRISPR sickle cell cure

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Peter Hotez and the public health issue of online harassment

STAT Virtual Event: The State of Biosimilars: What to Watch

What does generative AI mean for health care? We asked experts

Key House panel plots a new health care package

Duchenne breakthrough therapy leaves behind pioneering families

At Orexo, a ‘turning point’ for everything but digital health

Affirmative action in medical school literally saved lives

STAT Virtual Event: The State of Biosimilars: What to Watch

In age of alternative facts, a scholarly course on calling out crap

Cassava Sciences’ Alzheimer’s clinical trials should be halted

focus

A public scorecard can help hold safety

How dance can help nurses traumatized by Covid

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Doctors find melanoma drugs effective against rare brain cancer

Is there really a nursing shortage in the U.S.?

Key House panel plots a new health care package

knowledge

entertainment

focus

Wikipedia